Comparing Imatinib vs Sutent
| Imatinib | Sutent (sunitinib) |
|
|---|
| Imatinib | Sutent (sunitinib) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Dermatofibrosarcoma Protuberans, Chronic Eosinophilic Leukemia, Gastrointestinal Stromal Tumor, Hypereosinophilic Syndrome... View more |
Prescription only
Sutent is an oral capsule that may be taken once daily to treat certain types of RCC and other advanced cancers. It may be taken every day or for 4 weeks on, 2 weeks off schedule. It has been... View more |
Related suggestions Gastrointestinal Stromal Tumor
|
|||||||||||||||
| More about Imatinib | More about Sutent (sunitinib) | ||||||||||||||||
| Ratings & Reviews | |||||||||||||||||
|
Imatinib has an average rating of 8.8 out of 10 from a total of 47 ratings on Drugs.com. 87% of reviewers reported a positive effect, while 4% reported a negative effect. |
Sutent has an average rating of 7.6 out of 10 from a total of 30 ratings on Drugs.com. 67% of reviewers reported a positive effect, while 17% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||||||||||
|
View all Imatinib side effects |
View all Sutent side effects |
||||||||||||||||
| Drug Class | |||||||||||||||||
| Generic Availability | |||||||||||||||||
|
Lower cost generic |
|||||||||||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||||||||||
View all Imatinib prices |
View all Sutent prices |
||||||||||||||||
| Dosage Forms | |||||||||||||||||
|
|
||||||||||||||||
| Brand Names | |||||||||||||||||
| Gleevec, Imkeldi |
N/A |
||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||||||||||
|
40 hours |
60 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | |||||||||||||||||
|
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | |||||||||||||||||
|
A total of 766 drugs are known to interact with Imatinib:
|
A total of 490 drugs are known to interact with Sutent:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||||||||||
|
|
||||||||||||||||
| Disease Interactions | |||||||||||||||||
| First Approval Date | |||||||||||||||||
|
April 18, 2003 |
January 26, 2006 |
||||||||||||||||
| WADA Class View classifications | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| More Information | |||||||||||||||||
| Patient Resources | |||||||||||||||||
| Professional Resources | |||||||||||||||||
| Related Treatment Guide | |||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Hydrea
Hydrea is used for chronic myelogenous leukemia, head and neck cancer
Sprycel
Sprycel is used to treat chronic myeloid leukemia and acute lymphoblastic leukemia. Learn about ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Gleevec
Gleevec is targeted cancer therapy for specific types of leukemia (blood cancer), bone marrow ...
Cytoxan
Cytoxan is used for acute lymphocytic leukemia, acute nonlymphocytic leukemia, breast cancer ...
Tasigna
Tasigna (nilotinib) is used to treat Philadelphia chromosome positive chronic myeloid leukemia ...
Bosulif
Bosulif is a kinase inhibitor that may be used to treat adults and some children aged 1 year and ...
Ponatinib
Ponatinib is used to treat chronic myeloid leukemia and Philadelphia chromosome positive acute ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.